MedTrace Logo

Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes

NCT01713348 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2016-03-04

Study results available
· View outcomes & findings →

Summary

To understand if Multiple Daily Injections (MDI) managed subjects can improve glycaemic control by;

1. regularly checking and understanding Continuous Glucose data \& trend arrows at times other than the standard pre-meal bolus calculation test times and
2. review of their glucose profiles (inc. hypoglycaemic risks) with their Health Care Professional (HCP) and adjusting behaviours \& therapy from interpretation of the Continuous Glucose profiles.

Conditions

Interventions

DEVICE

FreeStyle Navigator

Masked CGM day 1 to 15, unmasked CGM days 15 to 100

DEVICE

Standard SMBG

Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100

Sponsors & Collaborators

  • Abbott Diabetes Care

    lead INDUSTRY

Principal Investigators

  • Ramzi Ajjan · St James Hospital, Leeds

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-05-31
Completion
2013-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01713348 on ClinicalTrials.gov